Low, Aislinn
Stiltner, Brendan
Nunez, Yaira Z.
Adhikari, Keyrun http://orcid.org/0000-0001-9129-1699
Deak, Joseph D. http://orcid.org/0000-0002-0540-6080
Pietrzak, Robert H.
Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Polimanti, Renato http://orcid.org/0000-0003-0745-6046
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
Article History
Received: 15 September 2023
Revised: 19 August 2024
Accepted: 21 August 2024
First Online: 28 August 2024
Competing interests
: RP received a research grant from Alkermes outside the scope of the present study. RP and JG are paid for their editorial work on the journal Complex Psychiatry. JG and HRK are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. HRK is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant to Sophrosyne Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which for the past three years was supported by Alkermes, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics, and is paid for his editorial work on the journal Alcohol: Clinical and Experimental Research. The other authors have no competing interests to report.